Our unique optimally engineered approach leverages an innovative proprietary platform to optimize the function of natural killer cells, thus maximizing cancer cell killing. We also focus on engineering strategies to enhance tumor homing and persistence in-vivo, and overcome exhaustion in the tumor microenvironment.
We are interested in working with leading academic centres, clinical institutions and industry partners to advance scientific understanding, preclinical and clinical evaluation, cell engineering and manufacturing capabilities to drive innovations in the field of NK cell therapies.
- ONK Therapeutics Presents Promising In-Vivo Data of its Optimized Affinity CD38 CAR-NK Candidate, Being Developed for the Treatment of Multiple Myeloma 29 August 2022
- ONK Therapeutics Brings in US Financial Experience with the Appointment of Dr. Allan Reine as Independent Non-Executive Director 23 March 2022
ONK Therapeutics featured in the Spring Edition of Nature BioPharma Dealmaker
Maximizing synergy and mitigating resistance: novel dual-targeted natural killer cell therapies for cancer